tradingkey.logo

Corvus Pharmaceuticals Inc <CRVS.OQ> expected to post a loss of 12 cents a share - Earnings Preview

ReutersMay 6, 2025 8:36 PM
  • Corvus Pharmaceuticals Inc CRVS.OQ CRVS.O is expected to show no change in quarterly revenue when it reports results on May 8 for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Corvus Pharmaceuticals Inc is for a loss of 12 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00​, above​ its last closing price of $3.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.12

-0.12

-0.18

Missed

-50.5

Sep. 30 2024

-0.11

-0.12

-0.60

Missed

-414.6

Jun. 30 2024

-0.12

-0.11

-0.04

Beat

65.2​

Mar. 31 2024

-0.14

-0.12

-0.12

Met

0

​​Dec. 31 2023

-0.12

-0.14

Missed

-17.6

Sep. 30 2023

-0.12

-0.12

-0.12

Met

1.6​

Jun. 30 2023

-0.16

-0.14

-0.14

Met

-0.5

Mar. 31 2023

-0.16

-0.16

-0.17

Missed

-8.3

This summary was machine generated May 6 at 20:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI